Our Team

Gwynneth Thomas, PhD


Gwynneth has spent her career at the intersection of business and science, with experience in product growth, operations and fundraising. She has worked with 50+ human health startups as they worked through various strategic business decisions. For several of those startups she led fundraising efforts, collectively helping them raise over $20M. She has also functioned in various roles within startup companies, including serving as the Director for Scientific Operations for the human microbiome company Diversigen, which was sold to Orasure in 2019. She has a strong focus on commercialization with experience in the areas of genomics, digital health, medical device and diagnostics. Gwynneth holds a PhD in Molecular Pathology and a Masters of Business Administration from Wake Forest University in Winston Salem, NC.

Dr. Antonio Benitz

Board Member

Tony is a Senior Advisor at Stonehaven Consulting. He retired from Boehringer-Ingelheim after a 35-year career in animal health. Tony served in senior roles in research and development in several companies, including Global Head of R&D for Pharmacia Animal Health and Novartis Animal Health. He played a key role in the integration of the R&D organizations following the acquisitions by Pfizer Animal Health and Elanco, respectively.

His experience includes bringing a range of new therapeutics and vaccines for animals to the market, and working closely with regulatory agencies in many international markets, including the Center of Veterinary Medicine, and the Food and Drug Agency in the U.S.

Mark Heffernan, PhD

Board Member

Mark is the CEO of Stonehaven Incubate. He has had a career spanning nearly two decades as co-founder and CEO in private and public companies, including the animal health monoclonal antibody company Nexvet Biopharma plc, which was sold to Zoetis in July 2017. For Nexvet he and his team raised over $80m during 2011-2017, including a Nasdaq IPO.

His experience spans both human biotechnology start-ups and animal health R&D companies, and he has raised over $150m in private and public capital raisings and built successful global teams to execute drug discovery and development. He has a PhD from Monash University.

Malcolm Thomas

Board Member

Malcolm is the CEO of Agile Sciences. Prior to this he was president and CEO of Arbovax, a biotechnology company commercializing a unique and innovative platform technology that can be used to make vaccines against insect-borne viral diseases.

Prior to Arbovax he was Vice President of Operations for StemCo Biomedical and before that, was Director of International Marketing for Bayer Biologicals and Vice President of Pacific Rim Operations for Becton Dickinson Biosciences.

During his tenure with Becton Dickinson as Vice President for Asia Pacific he lived in Singapore for five years.

He started his working life as a research scientist in the biochemistry department of the Wellcome Research Laboratories in the UK.

Dr. Simon Wheeler

Board Member

Simon is a veterinarian and strategic leader with over 20 years’ experience of the global animal health industry. He has previously held strategic, technical, marketing and innovation roles in various companies, including Pharmacia and Novartis.

He also reached senior positions in clinical veterinary academia in the UK and US, lecturing at international meetings and conducting research, as well as publishing three books and over 125 articles and chapters, and mentoring trainees. He has received several awards for teaching and contributions to veterinary surgery.

Simon is the CEO of animal diagnostics company, Vetsina and has recently held several consultancies, including Chief Operating Officer of Roslin Technologies, an Edinburgh-based biotech start up, and he was commercial consultant to Advanced Anaesthesia Specialists. He has supported various biotech companies as well as holding several board positions.

Cookie policy

We use necessary cookies to allow our site to function correctly. You can disable these via your browser settings but this site may not function correctly if you do so. We also use optional cookies to collect anonymised visitor statistics to help us identify issues and improve our web site. View our privacy policy here